Payment overview · 2025
General Payments
$861.73
48 reported records · 16 companies
Healthcare provider profile · identity verified
Leslie J Pollard, MD
Allopathic & Osteopathic Physicians|Family Medicine · EVANS, GA · NPI 1467494153
Verified facts
What the public records show
CMS Open Payments records show Leslie J Pollard, MD received $861.73 in general payments during 2025 across 48 reported records.
Novo Nordisk Inc accounted for 33.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $289.72 | 33.6% | 17 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $99.37 | 11.5% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $84.02 | 9.8% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $74.62 | 8.7% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $62.11 | 7.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.20 | 3.6% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $31.20 | 3.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.13 | 3.5% | 2 | 2025 |
| Vital Connect, Inc | Unresolved — no canonical attribution shown | $23.05 | 2.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.01 | 2.5% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.84 | 2.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.59 | 2.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.68 | 2.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.59 | 2.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.35 | 2.1% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.25 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $829.46 | 47 |
| Education | $32.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $208.56 | 12 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $122.41 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $81.16 | 5 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $62.11 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $55.02 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $54.41 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $44.96 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $44.96 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $40.46 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $31.20 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.20 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.20 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $30.13 | 2 | 2025 |
Source payment records
|
|||||
| VITALPATCH RTM Normalized: vitalpatch rtm |
Device | Vital Connect, Inc | $23.05 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.01 | 2 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $21.84 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.68 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.60 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.60 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.60 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 113 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 134 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 98 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
85 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
134 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
98 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
113 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 483 | 142 |
| Atorvastatin Calcium | Atorvastatin Calcium | 483 | 143 |
| Metformin Hcl | Metformin Hcl | 390 | 110 |
| Lisinopril | Lisinopril | 320 | 79 |
| Levothyroxine Sodium | Levothyroxine Sodium | 297 | 79 |
| Hydrochlorothiazide | Hydrochlorothiazide | 227 | 62 |
| Trazodone Hcl | Trazodone Hcl | 214 | 50 |
| Simvastatin | Simvastatin | 208 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 203 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 202 | 56 |
| Gabapentin | Gabapentin | 181 | 43 |
| Losartan Potassium | Losartan Potassium | 177 | 55 |
| Alprazolam | Alprazolam | 166 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 165 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 160 | 23 |
| Famotidine | Famotidine | 143 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 141 | 46 |
| Meloxicam | Meloxicam | 138 | 44 |
| Buspirone Hcl | Buspirone Hcl | 135 | 34 |
| Mounjaro | Tirzepatide | 134 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 132 | 20 |
| Omeprazole | Omeprazole | 130 | 37 |
| Glimepiride | Glimepiride | 129 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 128 | 25 |
| Prednisone | Prednisone | 127 | 73 |
| Allopurinol | Allopurinol | 125 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 123 | 39 |
| Tramadol Hcl | Tramadol Hcl | 122 | 29 |
| Eliquis | Apixaban | 113 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 113 | 15 |
| Clonazepam | Clonazepam | 112 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 111 | 31 |
| Bupropion Xl | Bupropion Hcl | 108 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 100 | 19 |
| Ozempic | Semaglutide | 98 | 17 |
| Donepezil Hcl | Donepezil Hcl | 97 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 97 | 24 |
| Jardiance | Empagliflozin | 85 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 81 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 21 |
| Montelukast Sodium | Montelukast Sodium | 80 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 77 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 73 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 71 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 18 |
| Carvedilol | Carvedilol | 68 | 25 |
| Glipizide | Glipizide | 66 | 17 |
| Estradiol | Estradiol | 65 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 16 |
| Potassium Chloride | Potassium Chloride | 60 | 19 |
| Pregabalin | Pregabalin | 60 | 11 |
| Sertraline Hcl | Sertraline Hcl | 60 | 20 |
| Furosemide | Furosemide | 59 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 19 |
| Mirtazapine | Mirtazapine | 58 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 57 | 16 |
| Azithromycin | Azithromycin | 55 | 48 |
| Diazepam | Diazepam | 55 | 11 |
| Lorazepam | Lorazepam | 54 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 51 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 50 | 17 |
| Atenolol | Atenolol | 44 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 44 | 31 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | suppressed |
| Finasteride | Finasteride | 43 | suppressed |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 24 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 42 | 16 |
| Topiramate | Topiramate | 42 | 11 |
| Baclofen | Baclofen | 41 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 11 |
| Mupirocin | Mupirocin | 41 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | 11 |
| Glipizide Er | Glipizide | 38 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 37 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 26 |
| Fluconazole | Fluconazole | 36 | 26 |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Celecoxib | Celecoxib | 35 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | 13 |
| Klor-Con M20 | Potassium Chloride | 32 | suppressed |
| Nifedipine Er | Nifedipine | 31 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 21 |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Naproxen | Naproxen | 30 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 17 |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 12 |
| Primidone | Primidone | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 21 |
| Nortriptyline Hcl | Nortriptyline Hcl | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 19 |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 11 |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Febuxostat | Febuxostat | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Wegovy | Semaglutide | 15 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Keppra | Levetiracetam | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Dilantin | Phenytoin | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $861.73 · 48 records | Novo Nordisk Inc | ABRYSVO, CAPLYTA, COMIRNATY, CONTRAVE, DUPIXENT, ELIQUIS, FARXIGA, GEMTESA, Korlym, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, Sunosi, UBRELVY, VITALPATCH RTM, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error